Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results

...lly completed, and we advanced another compound, a vmat2 inhibitor, now ready for clinical development. We ...noamine Transporter 2 Inhibitor (VMAT2 ) vmat2 is a protein concentrated in the human brain that ...ons. The Company has identified a highly selective vmat2 inhibitor that is effective in regulating the leve...

FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine for Chorea Associated With Huntington Disease

... associated with HD. A highly selective and reversible centrally-acting dopamine depleting drug, tetrabenazine works by inhibiting a molecule known as vmat2 (vesicular monoamine transporter 2). Adverse events reported with tetrabenazine, most of which were addressed by titrating down the dose, included d...

VMAT2 in Biological Technology

Neurocrine Biosciences Reports Second Quarter 2009 Results

...h is elagolix, and have just put another compound, vmat2 inhibitor into Phase I trials. We also continue t...ent; enrollment of 50 subjects is planned. vmat2 Update The highly selective blockade of the Ves...including risk that the Company's urocortin 2, and vmat2 clinical candidates will not proceed to later stag...

Neurocrine Biosciences Reports First Quarter 2009 Results

...noamine Transporter 2 Inhibitor (VMAT2 ) vmat2 is a protein concentrated in the human brain that ...neurons. Neurocrine identified a highly selective vmat2 inhibitor that is effective in regulating the leve...mpany's urocortin 2, CRF1 receptor antagonist, and vmat2 clinical candidates will not proceed to later stag...

Neurocrine Announces Work Force Restructuring

... are going to find continued success in their careers," said Kevin C. Gorman President & CEO. "We will maintain our efforts on elagolix, move our vmat2 program into the clinic, and focus on the other high value assets. We continue to conservatively manage our cash resources while advancing our pipeli...

Neurocrine Biosciences Reports Third Quarter 2008 Results

...studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our vmat2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making ...

VMAT2 in Biological Products

Anti-Vesicular Monoamine Transporter 2 (VMAT2) Polyclonal Antibody, Unconjugated from CHEMICON

Description:...rter 2 (VMAT2). An antibody made to the C-terminal vmat2 peptide detected a major band at ~55 kDa in postnuclear supernatants of CHO transfected with vmat2 and not in wild type cells (2). Some additional ba... molecular weight bands may represent glycosylated vmat2 (2,3)....
Company:CHEMICON